US6849708B1
(en)
|
1986-05-05 |
2005-02-01 |
The General Hospital Corporation |
Insulinotropic hormone and uses thereof
|
US7138486B2
(en)
|
1986-05-05 |
2006-11-21 |
The General Hospital Corporation |
Insulinotropic hormone derivatives and uses thereof
|
US5614492A
(en)
*
|
1986-05-05 |
1997-03-25 |
The General Hospital Corporation |
Insulinotropic hormone GLP-1 (7-36) and uses thereof
|
DK36492D0
(da)
*
|
1992-03-19 |
1992-03-19 |
Novo Nordisk As |
Praeparat
|
USRE37302E1
(en)
*
|
1992-03-19 |
2001-07-31 |
Novo Nordisk A/S |
Peptide
|
DK36392D0
(da)
*
|
1992-03-19 |
1992-03-19 |
Novo Nordisk As |
Anvendelse af kemisk forbindelse
|
JP2575298B2
(ja)
*
|
1992-06-15 |
1997-01-22 |
フアイザー・インコーポレイテツド |
グルカゴン様ペプチド及びインシュリノトロピン誘導体
|
US6284727B1
(en)
*
|
1993-04-07 |
2001-09-04 |
Scios, Inc. |
Prolonged delivery of peptides
|
NZ250844A
(en)
*
|
1993-04-07 |
1996-03-26 |
Pfizer |
Treatment of non-insulin dependant diabetes with peptides; composition
|
US5705483A
(en)
*
|
1993-12-09 |
1998-01-06 |
Eli Lilly And Company |
Glucagon-like insulinotropic peptides, compositions and methods
|
EP0658568A1
(en)
*
|
1993-12-09 |
1995-06-21 |
Eli Lilly And Company |
Glucagon-like insulinotropic peptides, compositions and methods
|
DK144093D0
(ja)
*
|
1993-12-23 |
1993-12-23 |
Novo Nordisk As |
|
GB9409496D0
(en)
*
|
1994-05-12 |
1994-06-29 |
London Health Ass |
Method for improving glycaemic control in diabetes
|
US5574008A
(en)
|
1994-08-30 |
1996-11-12 |
Eli Lilly And Company |
Biologically active fragments of glucagon-like insulinotropic peptide
|
US5512549A
(en)
*
|
1994-10-18 |
1996-04-30 |
Eli Lilly And Company |
Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
|
US5990077A
(en)
*
|
1995-04-14 |
1999-11-23 |
1149336 Ontario Inc. |
Glucagon-like peptide-2 and its therapeutic use
|
WO1996036883A1
(en)
*
|
1995-05-17 |
1996-11-21 |
Novo Nordisk A/S |
Immunoassay for glucagon like protein 1 (glp-1) in plasma
|
US6852690B1
(en)
|
1995-08-22 |
2005-02-08 |
Amylin Pharmaceuticals, Inc. |
Method and composition for enhanced parenteral nutrition
|
DE19616486C5
(de)
*
|
1996-04-25 |
2016-06-30 |
Royalty Pharma Collection Trust |
Verfahren zur Senkung des Blutglukosespiegels in Säugern
|
EP1566180A3
(en)
*
|
1996-08-30 |
2007-08-08 |
Eli Lilly & Company |
Use of GLP-1 or Analogs in Treatment of Myocardial Infarction
|
PL192359B1
(pl)
*
|
1996-08-30 |
2006-10-31 |
Novo Nordisk As |
Pochodna GLP-1(7-37) lub analogu GLP-1(7-37), środek farmaceutyczny oraz zastosowanie pochodnej GLP-1(7-37) lub analogu GLP-1(7-37)
|
EP0929576A1
(en)
*
|
1996-08-30 |
1999-07-21 |
Novo Nordisk A/S |
Glp-2 derivatives
|
US6268343B1
(en)
|
1996-08-30 |
2001-07-31 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
US6006753A
(en)
*
|
1996-08-30 |
1999-12-28 |
Eli Lilly And Company |
Use of GLP-1 or analogs to abolish catabolic changes after surgery
|
US6277819B1
(en)
*
|
1996-08-30 |
2001-08-21 |
Eli Lilly And Company |
Use of GLP-1 or analogs in treatment of myocardial infarction
|
US6458924B2
(en)
|
1996-08-30 |
2002-10-01 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
US7235627B2
(en)
|
1996-08-30 |
2007-06-26 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
UA65549C2
(uk)
|
1996-11-05 |
2004-04-15 |
Елі Ліллі Енд Компані |
Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
|
WO1998030231A1
(en)
|
1997-01-07 |
1998-07-16 |
Amylin Pharmaceuticals, Inc. |
Use of exendins and agonists thereof for the reduction of food intake
|
JP2002510193A
(ja)
*
|
1997-03-31 |
2002-04-02 |
イーライ・リリー・アンド・カンパニー |
グルカゴン様ペプチド−1類似体
|
US7157555B1
(en)
|
1997-08-08 |
2007-01-02 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
WO1999014239A1
(de)
*
|
1997-09-12 |
1999-03-25 |
Wolf Georg Forssmann |
Zusammensetzung zur therapie von diabetes mellitus und fettsucht
|
US7223725B1
(en)
|
1997-11-14 |
2007-05-29 |
Amylin Pharmaceuticals, Inc. |
Exendin agonist compounds
|
EP1066314B1
(en)
|
1997-11-14 |
2007-12-26 |
Amylin Pharmaceuticals, Inc. |
Novel exendin agonist compounds
|
JP2001525371A
(ja)
*
|
1997-12-05 |
2001-12-11 |
イーライ・リリー・アンド・カンパニー |
Glp−1製剤
|
CA2819705C
(en)
|
1998-02-02 |
2014-07-08 |
Trustees Of Tufts College |
Method of regulating glucose metabolism, and reagents related thereto
|
EP1056775B1
(en)
|
1998-02-27 |
2010-04-28 |
Novo Nordisk A/S |
Glp-1 derivatives of glp-1 and exendin with protracted profile of action
|
DE69916811T2
(de)
*
|
1998-02-27 |
2005-04-14 |
Novo Nordisk A/S |
Glp-1 derivate mit einem helix-gehalt über 25 %, die partiell strukturierte mizellenartige aggregate bilden
|
EP1062240B1
(en)
|
1998-02-27 |
2010-04-28 |
Novo Nordisk A/S |
N-terminally modified glp-1 derivatives
|
FR2777283B1
(fr)
*
|
1998-04-10 |
2000-11-24 |
Adir |
Nouveaux composes peptidiques analogues du glucagon-peptide- 1 (7-37), leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
JPH11328947A
(ja)
|
1998-05-18 |
1999-11-30 |
Nec Corp |
大規模fifo回路
|
DE19823831A1
(de)
|
1998-05-28 |
1999-12-02 |
Probiodrug Ges Fuer Arzneim |
Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
|
DE19828114A1
(de)
|
1998-06-24 |
2000-01-27 |
Probiodrug Ges Fuer Arzneim |
Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
|
DE19828113A1
(de)
|
1998-06-24 |
2000-01-05 |
Probiodrug Ges Fuer Arzneim |
Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
|
EP1306091A3
(en)
|
1998-07-31 |
2003-05-21 |
Novo Nordisk A/S |
Stimulation of beta cell proliferation
|
EP1666054A1
(en)
|
1998-08-28 |
2006-06-07 |
Eli Lilly & Company |
Method for administering insulinotropic peptides
|
BR9913857A
(pt)
|
1998-09-17 |
2001-06-12 |
Lilly Co Eli |
Formulações de proteìna
|
US6461834B1
(en)
|
1998-11-06 |
2002-10-08 |
Bionebraska, Inc. |
Clostripain catalyzed amidation of peptides
|
WO2000034331A2
(en)
*
|
1998-12-07 |
2000-06-15 |
Societe De Conseils De Recherches Et D'applications Scientifiques Sas |
Analogues of glp-1
|
ZA200304047B
(en)
*
|
1998-12-07 |
2004-04-28 |
Sod Conseils Rech Applic |
Analogues of GLP-1.
|
BR9916027A
(pt)
*
|
1998-12-07 |
2001-08-28 |
Sod Conseils Rech Applic |
Análogos de glp-1
|
US7425541B2
(en)
*
|
1998-12-11 |
2008-09-16 |
Medarex, Inc. |
Enzyme-cleavable prodrug compounds
|
EP1600162A1
(en)
|
1998-12-22 |
2005-11-30 |
Eli Lilly & Company |
Shelf-stable formulation of glucagon-like peptide-1
|
US6927214B1
(en)
|
1999-01-15 |
2005-08-09 |
Novo Nordisk A/S |
Non-peptide GLP-1 agonists
|
US6451987B1
(en)
|
1999-03-15 |
2002-09-17 |
Novo Nordisk A/S |
Ion exchange chromatography of proteins and peptides
|
ATE509028T1
(de)
*
|
1999-03-15 |
2011-05-15 |
Novo Nordisk As |
Ionen-austausch-chromatographische trennung von glp-1 und verwandten peptiden
|
US6444788B1
(en)
|
1999-03-15 |
2002-09-03 |
Novo Nordisk A/S |
Ion exchange chromatography of GLP-1, analogs and derivatives thereof
|
US6451974B1
(en)
|
1999-03-17 |
2002-09-17 |
Novo Nordisk A/S |
Method of acylating peptides and novel acylating agents
|
US20050272652A1
(en)
|
1999-03-29 |
2005-12-08 |
Gault Victor A |
Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
|
WO2000069911A1
(en)
|
1999-05-17 |
2000-11-23 |
Conjuchem, Inc. |
Long lasting insulinotropic peptides
|
US6514500B1
(en)
|
1999-10-15 |
2003-02-04 |
Conjuchem, Inc. |
Long lasting synthetic glucagon like peptide {GLP-!}
|
US6309633B1
(en)
*
|
1999-06-19 |
2001-10-30 |
Nobex Corporation |
Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
|
DE19940130A1
(de)
|
1999-08-24 |
2001-03-01 |
Probiodrug Ges Fuer Arzneim |
Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung
|
AU784477B2
(en)
*
|
1999-11-19 |
2006-04-13 |
Shire Human Genetic Therapies, Inc. |
Nucleic acid construct for optimized production of products
|
EP1741447B1
(en)
|
2000-01-21 |
2013-09-18 |
Novartis AG |
Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents
|
WO2001066135A1
(en)
|
2000-03-08 |
2001-09-13 |
Novo Nordisk A/S |
Lowering serum lipids
|
EP1695983B1
(en)
|
2000-06-16 |
2009-03-04 |
Eli Lilly & Company |
Glucagon-like peptide-1 analogs
|
AR033390A1
(es)
|
2000-08-22 |
2003-12-17 |
Novartis Ag |
Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
|
AU2002213925A1
(en)
|
2000-09-18 |
2002-03-26 |
Osteometer Biotech As |
Use of glp-1 and flp-2 peptides for treatment of bone disorders
|
US7132104B1
(en)
|
2000-10-27 |
2006-11-07 |
Probiodrug Ag |
Modulation of central nervous system (CNS) dipeptidyl peptidase IV (DPIV) -like activity for the treatment of neurological and neuropsychological disorders
|
AU2002224124A1
(en)
|
2000-12-01 |
2002-06-11 |
Takeda Chemical Industries Ltd. |
Method for producing preparation containing bioactive substance
|
US7199217B2
(en)
|
2000-12-13 |
2007-04-03 |
Eli Lilly And Company |
Amidated glucagon-like peptide-1
|
US6573237B2
(en)
|
2001-03-16 |
2003-06-03 |
Eli Lilly And Company |
Protein formulations
|
US6890905B2
(en)
|
2001-04-02 |
2005-05-10 |
Prosidion Limited |
Methods for improving islet signaling in diabetes mellitus and for its prevention
|
CN1162446C
(zh)
|
2001-05-10 |
2004-08-18 |
上海华谊生物技术有限公司 |
促胰岛素分泌肽衍生物
|
US20030130199A1
(en)
|
2001-06-27 |
2003-07-10 |
Von Hoersten Stephan |
Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
|
US7368421B2
(en)
|
2001-06-27 |
2008-05-06 |
Probiodrug Ag |
Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
|
DE10150203A1
(de)
|
2001-10-12 |
2003-04-17 |
Probiodrug Ag |
Peptidylketone als Inhibitoren der DPIV
|
EP1432730A4
(en)
|
2001-08-23 |
2006-10-11 |
Lilly Co Eli |
GLP-1 ANALOGUES (GLUCAGON-LIKE PEPTIDE 1)
|
US6844316B2
(en)
|
2001-09-06 |
2005-01-18 |
Probiodrug Ag |
Inhibitors of dipeptidyl peptidase I
|
US6864069B2
(en)
|
2001-10-05 |
2005-03-08 |
Bayer Pharmaceuticals Corporation |
Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
|
AR036711A1
(es)
|
2001-10-05 |
2004-09-29 |
Bayer Corp |
Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
|
US7041646B2
(en)
|
2001-10-05 |
2006-05-09 |
Bayer Pharmaceuticals Corporation |
Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists
|
EP1463751B1
(en)
|
2001-12-21 |
2013-05-22 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
EP2409569B1
(en)
|
2002-02-20 |
2017-08-16 |
Emisphere Technologies, Inc. |
Method for administering GLP-1 molecules
|
KR20040095241A
(ko)
|
2002-02-28 |
2004-11-12 |
프로시디온 리미티드 |
글루타미닐계 dpiv 억제제
|
JP5685355B2
(ja)
|
2002-07-04 |
2015-03-18 |
ジーランド ファーマ アクティーゼルスカブ |
Glp−1および糖尿病の処置方法
|
CA2497794A1
(en)
*
|
2002-09-06 |
2004-03-18 |
Bayer Pharmaceuticals Corporation |
Modified glp-1 receptor agonists and their pharmacological methods of use
|
US7273921B2
(en)
|
2002-09-25 |
2007-09-25 |
Novo Nordisk A/S |
Method for producing acylated peptides
|
WO2004029081A2
(en)
|
2002-09-25 |
2004-04-08 |
Theratechnologies Inc. |
Modified glp-1 peptides with increased biological potency
|
WO2004035624A2
(en)
|
2002-10-14 |
2004-04-29 |
Novo Nordisk A/S |
Glucagon - like peptide - 2 variants
|
US7790681B2
(en)
|
2002-12-17 |
2010-09-07 |
Amylin Pharmaceuticals, Inc. |
Treatment of cardiac arrhythmias with GLP-1 receptor ligands
|
US7847063B2
(en)
|
2003-03-28 |
2010-12-07 |
Sanwa Kagaku Kenkyusho Co., Ltd. |
GLP-1 derivative
|
PT1620082E
(pt)
|
2003-05-05 |
2010-06-11 |
Probiodrug Ag |
Utilização médica de inibidores de ciclases de glutaminilo e glutamato para o tratamento da doença de alzheimer e síndrome de down
|
EP1620091B1
(en)
|
2003-05-05 |
2010-03-31 |
Probiodrug AG |
Inhibitors of glutaminyl cyclase
|
US7008957B2
(en)
|
2003-07-25 |
2006-03-07 |
Sanofi-Aventis Deutschland Gmbh |
Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments
|
US7094800B2
(en)
|
2003-07-25 |
2006-08-22 |
Sanofi-Aventis Deutschland Gmbh |
Cyanopyrrolidides, process for their preparation and their use as medicaments
|
US7094794B2
(en)
|
2003-07-28 |
2006-08-22 |
Sanofi-Aventis Deutschland Gmbh |
Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use
|
DE10335092B3
(de)
|
2003-08-01 |
2005-02-03 |
Aventis Pharma Deutschland Gmbh |
Substituierte Benzoylureido-o-benzoylamide, Verfahren zu deren Herstellung und deren Verwendung
|
EP1664108B1
(en)
|
2003-08-21 |
2009-10-14 |
Novo Nordisk A/S |
Separation of polypeptides comprising a racemized amino acid
|
TW200526254A
(en)
|
2003-09-19 |
2005-08-16 |
Novo Nordisk As |
Novel GLP-1 derivatives
|
DK1675578T3
(da)
|
2003-10-15 |
2013-08-26 |
Probiodrug Ag |
Inhibitorer af glutaminyl- og glutamatcyclaser til behandling af de neurodegenerative sygdomme FBD og FDD
|
KR101243648B1
(ko)
|
2003-11-20 |
2013-03-14 |
노보 노르디스크 에이/에스 |
제조 및 주사 장치용에 최적인 프로필렌 글리콜 함유펩티드 제제
|
EP1694356B1
(en)
|
2003-12-09 |
2011-02-16 |
Novo Nordisk A/S |
Regulation of food preference using glp-1 agonists
|
JP2007536214A
(ja)
|
2003-12-16 |
2007-12-13 |
ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス |
Glp−1類似体
|
JP2007514752A
(ja)
*
|
2003-12-16 |
2007-06-07 |
ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス |
Glp−1医薬組成物
|
AU2004298424A1
(en)
|
2003-12-18 |
2005-06-30 |
Novo Nordisk A/S |
Novel GLP-1 compounds
|
AU2005203925A1
(en)
*
|
2004-01-08 |
2005-07-21 |
Theratechnologies Inc. |
Glucagon-Like Peptide-1 analogs with long duration of action
|
US8076288B2
(en)
|
2004-02-11 |
2011-12-13 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides having glucose lowering activity
|
EP1718665B1
(en)
|
2004-02-11 |
2013-04-10 |
Amylin Pharmaceuticals, LLC |
Hybrid polypeptides with selectable properties
|
WO2005120492A1
(en)
|
2004-06-11 |
2005-12-22 |
Novo Nordisk A/S |
Counteracting drug-induced obesity using glp-1 agonists
|
AU2005327906B2
(en)
*
|
2004-07-21 |
2010-05-13 |
Ambrx, Inc. |
Biosynthetic polypeptides utilizing non-naturally encoded amino acids
|
CA2589800A1
(en)
|
2004-12-02 |
2006-06-08 |
Domantis Limited |
Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
|
US8404637B2
(en)
|
2005-02-11 |
2013-03-26 |
Amylin Pharmaceuticals, Llc |
GIP analog and hybrid polypeptides with selectable properties
|
US8263545B2
(en)
|
2005-02-11 |
2012-09-11 |
Amylin Pharmaceuticals, Inc. |
GIP analog and hybrid polypeptides with selectable properties
|
US8603972B2
(en)
|
2005-03-18 |
2013-12-10 |
Novo Nordisk A/S |
Extended GLP-1 compounds
|
TWI362392B
(en)
|
2005-03-18 |
2012-04-21 |
Novo Nordisk As |
Acylated glp-1 compounds
|
US8946149B2
(en)
|
2005-04-11 |
2015-02-03 |
Amylin Pharmaceuticals, Llc |
Use of exendin and analogs thereof to delay or prevent cardiac remodeling
|
WO2006126673A1
(ja)
*
|
2005-05-27 |
2006-11-30 |
Daiichi Sankyo Company, Limited |
組み合わせによる糖尿病治療薬
|
EP2330125A3
(en)
|
2005-08-11 |
2012-12-12 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides with selectable properties
|
EP2330124B1
(en)
|
2005-08-11 |
2015-02-25 |
Amylin Pharmaceuticals, LLC |
Hybrid polypeptides with selectable properties
|
GT200600381A
(es)
|
2005-08-25 |
2007-03-28 |
|
Compuestos organicos
|
ZA200802857B
(en)
|
2005-09-14 |
2009-09-30 |
Takeda Pharmaceutical |
Dipeptidyl peptidase inhibitors for treating diabetes
|
WO2007033266A2
(en)
|
2005-09-14 |
2007-03-22 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors for treating diabetis
|
KR101368988B1
(ko)
|
2005-09-16 |
2014-02-28 |
다케다 야쿠힌 고교 가부시키가이샤 |
디펩티딜 펩티다제 억제제
|
PL1767545T3
(pl)
|
2005-09-22 |
2010-04-30 |
Biocompatibles Uk Ltd |
Polipeptydy fuzyjne GLP-1 (glukagonopodobny peptyd-1) o zwiększonej odporności na peptydazy
|
WO2007051987A1
(en)
*
|
2005-11-01 |
2007-05-10 |
Activotec Spp Limited |
Insulinotropic compounds and uses thereof
|
CA2628241C
(en)
|
2005-11-07 |
2016-02-02 |
Indiana University Research And Technology Corporation |
Glucagon analogs exhibiting physiological solubility and stability
|
CN100374462C
(zh)
*
|
2005-11-21 |
2008-03-12 |
大连帝恩生物工程有限公司 |
截短胰高血糖素样肽1(sGLP-1)、制法及其应用
|
JPWO2007063907A1
(ja)
*
|
2005-11-30 |
2009-05-07 |
塩野義製薬株式会社 |
ペプチド糖鎖付加体およびそれを有効成分とする医薬
|
EP2364735A3
(en)
|
2005-12-16 |
2012-04-11 |
Nektar Therapeutics |
Branched PEG conjugates of GLP-1
|
EP2573111A1
(en)
|
2006-04-20 |
2013-03-27 |
Amgen Inc. |
GLP-1 compounds
|
WO2007128757A2
(en)
*
|
2006-05-02 |
2007-11-15 |
Actogenix N.V. |
Microbial intestinal delivery of obesity related peptides
|
US8497240B2
(en)
|
2006-08-17 |
2013-07-30 |
Amylin Pharmaceuticals, Llc |
DPP-IV resistant GIP hybrid polypeptides with selectable properties
|
TW200838536A
(en)
|
2006-11-29 |
2008-10-01 |
Takeda Pharmaceutical |
Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
|
KR20150116465A
(ko)
|
2007-02-15 |
2015-10-15 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
글루카곤/glp-1 수용체 공동-항진물질
|
WO2009030738A1
(en)
|
2007-09-05 |
2009-03-12 |
Novo Nordisk A/S |
Glucagon-like peptide-1 derivatives and their pharmaceutical use
|
JP2010538049A
(ja)
|
2007-09-05 |
2010-12-09 |
ノボ・ノルデイスク・エー/エス |
切断型glp−1誘導体及びその治療的使用
|
CA2702289A1
(en)
|
2007-10-30 |
2009-05-07 |
Indiana University Research And Technology Corporation |
Compounds exhibiting glucagon antagonist and glp-1 agonist activity
|
WO2009099763A1
(en)
|
2008-01-30 |
2009-08-13 |
Indiana University Research And Technology Corporation |
Ester-based peptide prodrugs
|
EA018471B1
(ru)
|
2008-03-31 |
2013-08-30 |
Глаксо Груп Лимитед |
Слитые конструкции и конъюгаты лекарственного средства
|
NZ589847A
(en)
|
2008-06-17 |
2013-01-25 |
Univ Indiana Res & Tech Corp |
Glucagon/glp-1 receptor co-agonists
|
EP2952202B1
(en)
|
2008-06-17 |
2017-10-18 |
Indiana University Research and Technology Corporation |
Gip-based mixed agonists for treatment of metabolic disorders and obesity
|
CN102112157B
(zh)
|
2008-08-06 |
2013-05-29 |
诺沃-诺迪斯克保健股份有限公司 |
具有延长的体内效能的缀合蛋白
|
WO2010054326A2
(en)
|
2008-11-07 |
2010-05-14 |
The General Hospital Corporation |
C-terminal fragments of glucagon-like peptide-1 (glp-1)
|
EP2373391A1
(en)
|
2008-12-08 |
2011-10-12 |
Novo Nordisk A/S |
Counter current purification of polypeptides
|
PL2373681T3
(pl)
*
|
2008-12-10 |
2017-07-31 |
Glaxosmithkline Llc |
Kompozycje farmaceutyczne albiglutydu
|
AR074811A1
(es)
*
|
2008-12-19 |
2011-02-16 |
Univ Indiana Res & Tech Corp |
Profarmaco de peptido de la superfamilia de glucagon basados en amida
|
CN102292349B
(zh)
|
2009-01-22 |
2016-04-13 |
诺沃—诺迪斯克保健股份有限公司 |
稳定的生长激素化合物
|
KR20110137819A
(ko)
|
2009-03-27 |
2011-12-23 |
글락소 그룹 리미티드 |
약물 융합체 및 컨쥬게이트
|
MX2011012199A
(es)
|
2009-05-15 |
2011-12-08 |
Novartis Ag |
Derivados de benzoxazolona como inhibidores de la sintasa de aldosterona.
|
WO2010130796A1
(en)
|
2009-05-15 |
2010-11-18 |
Novartis Ag |
Aryl pyridine as aldosterone synthase inhibitors
|
EA201101672A1
(ru)
|
2009-05-28 |
2012-06-29 |
Новартис Аг |
Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
|
BRPI1011657A2
(pt)
|
2009-05-28 |
2019-04-16 |
Novartis Ag |
derivados aminopropiônicos substituídos como inibidores de neprilisina
|
KR20120087875A
(ko)
|
2009-06-16 |
2012-08-07 |
인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 |
Gip 수용체-활성 글루카곤 화합물
|
US8841249B2
(en)
|
2009-08-06 |
2014-09-23 |
Novo Nordisk A/S |
Growth hormones with prolonged in-vivo efficacy
|
SG10201406063XA
(en)
|
2009-09-30 |
2014-11-27 |
Glaxo Group Ltd |
Drug fusions and conjugates with extended half life
|
WO2011041293A1
(en)
|
2009-09-30 |
2011-04-07 |
Takeda Pharmaceutical Company Limited |
Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
|
JP5654608B2
(ja)
|
2009-11-17 |
2015-01-14 |
ノバルティス アーゲー |
アルドステロンシンターゼ阻害剤としてのアリール−ピリジン誘導体
|
JO2967B1
(en)
|
2009-11-20 |
2016-03-15 |
نوفارتس ايه جي |
Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
|
ES2472446T3
(es)
|
2009-11-30 |
2014-07-01 |
Novartis Ag |
Derivados de imidazol como inhibidores de aldosterona sintasa
|
PL2513140T3
(pl)
*
|
2009-12-16 |
2016-04-29 |
Novo Nordisk As |
Podwójnie acylowane pochodne glp-1
|
TWI508737B
(zh)
|
2010-01-22 |
2015-11-21 |
諾佛 儂迪克股份有限公司 |
具有延長的活體內功效的生長激素
|
US9211342B2
(en)
|
2010-01-22 |
2015-12-15 |
Novo Nordisk Healthcare Ag |
Stable growth hormone compounds resistant to proteolytic degradation
|
MX2012008603A
(es)
|
2010-01-27 |
2013-01-25 |
Univ Indiana Res & Tech Corp |
Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad.
|
SI2531501T1
(sl)
|
2010-02-03 |
2014-04-30 |
Takeda Pharmaceutical Company Limited |
Inhibitorji kinaze-1, ki regulirajo signal apoptoze
|
EP2555791B1
(en)
|
2010-04-09 |
2017-11-01 |
Sinai Health System |
Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist
|
CA2797033C
(en)
|
2010-04-22 |
2021-10-19 |
Longevity Biotech, Inc. |
Highly active polypeptides and methods of making and using the same
|
CN107129538B
(zh)
|
2010-04-27 |
2021-07-16 |
西兰制药公司 |
Glp-1受体激动剂和胃泌素的肽缀合物及其用途
|
JP5827218B2
(ja)
|
2010-04-30 |
2015-12-02 |
株式会社三和化学研究所 |
生理活性物質等の生体内安定性向上のためのペプチド及び生体内安定性が向上した生理活性物質
|
RU2557301C2
(ru)
|
2010-05-17 |
2015-07-20 |
Бетта Фармасьютикалз Ко.,Лтд |
Новые аналоги глюкагон-подобного пептида, композиция и способ применения
|
WO2011163012A2
(en)
|
2010-06-24 |
2011-12-29 |
Indiana University Research And Technology Corporation |
Amide based glucagon superfamily peptide prodrugs
|
CN103119057B
(zh)
|
2010-06-24 |
2016-06-15 |
印第安纳大学研究及科技有限公司 |
基于酰胺的胰岛素前药
|
WO2012054822A1
(en)
|
2010-10-22 |
2012-04-26 |
Nektar Therapeutics |
Pharmacologically active polymer-glp-1 conjugates
|
WO2012054861A1
(en)
|
2010-10-22 |
2012-04-26 |
Nektar Therapeutics |
Glp-1 polymer conjugates having a releasable linkage
|
WO2012061466A2
(en)
|
2010-11-02 |
2012-05-10 |
The General Hospital Corporation |
Methods for treating steatotic disease
|
US8673974B2
(en)
|
2010-11-16 |
2014-03-18 |
Novartis Ag |
Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
|
US8877815B2
(en)
|
2010-11-16 |
2014-11-04 |
Novartis Ag |
Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
|
EP3326620B1
(en)
|
2010-12-16 |
2020-03-04 |
Novo Nordisk A/S |
Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2- hydroxybenzoyl)amino)caprylic acid
|
BR112013015389A2
(pt)
|
2010-12-22 |
2016-11-22 |
Univ Indiana Res & Tech Corp |
análogo de glucagon exibindo atividade de receptor gip
|
WO2012121302A1
(ja)
|
2011-03-08 |
2012-09-13 |
株式会社 三和化学研究所 |
分析方法
|
WO2012136790A1
(en)
|
2011-04-07 |
2012-10-11 |
Glaxo Group Limited |
Compositions comprising fusion proteins or conjugates with an improved half -life
|
WO2012136792A2
(en)
|
2011-04-07 |
2012-10-11 |
Glaxo Group Limited |
Cck compositions
|
HUE031405T2
(en)
|
2011-04-12 |
2017-07-28 |
Novo Nordisk As |
Double-acylated GLP-1 derivatives
|
RU2014101697A
(ru)
|
2011-06-22 |
2015-07-27 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Коагонисты рецепторов глюкагона/glp-1
|
CN103857408B
(zh)
|
2011-06-22 |
2017-04-12 |
印第安那大学科技研究公司 |
胰高血糖素/glp‑1受体协同激动剂
|
EP2729493B1
(en)
|
2011-07-04 |
2020-06-10 |
IP2IPO Innovations Limited |
Novel compounds and their effects on feeding behaviour
|
WO2013006692A2
(en)
|
2011-07-06 |
2013-01-10 |
The General Hospital Corporation |
Methods of treatment using a pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1)
|
WO2013060887A1
(en)
*
|
2011-10-28 |
2013-05-02 |
Pharis Biotec Gmbh |
A polypeptide for the protection against heart ischemia-reperfusion injury
|
WO2013064669A1
(en)
|
2011-11-03 |
2013-05-10 |
Zealand Pharma A/S |
Glp-1 receptor agonist peptide gastrin conjugates
|
WO2013083826A2
(en)
*
|
2011-12-09 |
2013-06-13 |
Novo Nordisk A/S |
Glp-1 agonists
|
PT2827845T
(pt)
|
2012-03-22 |
2019-03-29 |
Novo Nordisk As |
Composições compreendendo um agente de entrega e sua preparação
|
MY171146A
(en)
|
2012-03-22 |
2019-09-27 |
Novo Nordisk As |
Compositions of glp-1 peptides and preparation thereof
|
CA2873536A1
(en)
|
2012-05-16 |
2013-11-21 |
Glaxo Group Limited |
Polypeptide loaded poca nanoparticles for oral administration
|
EP2863895B1
(en)
|
2012-06-20 |
2021-04-14 |
Novo Nordisk A/S |
Tablet formulation comprising a peptide and a delivery agent
|
EP2864351B1
(en)
|
2012-06-21 |
2016-08-10 |
Indiana University Research and Technology Corporation |
Glucagon analogs exhibiting gip receptor activity
|
JP6224586B2
(ja)
|
2012-07-10 |
2017-11-01 |
武田薬品工業株式会社 |
注射用製剤
|
CN104662038B
(zh)
|
2012-07-23 |
2018-11-06 |
西兰制药公司 |
胰高血糖素类似物
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
UY35144A
(es)
|
2012-11-20 |
2014-06-30 |
Novartis Ag |
Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
|
LT2956464T
(lt)
|
2013-02-14 |
2018-07-10 |
Novartis Ag |
Pakeisti bisfenilbutanoinės fosfonrūgšties dariniai, kaip nep (neutralios endopeptidazės) inhibitoriai
|
US9789164B2
(en)
|
2013-03-15 |
2017-10-17 |
Longevity Biotech, Inc. |
Peptides comprising non-natural amino acids and methods of making and using the same
|
WO2014166836A1
(en)
|
2013-04-05 |
2014-10-16 |
Novo Nordisk A/S |
Growth hormone compound formulation
|
UY35548A
(es)
|
2013-05-02 |
2014-11-28 |
Glaxosmithkline Ip No 2 Ltd |
Péptidos terapéuticos para el tratamiento de trastornos metabólicos.
|
MX2016001020A
(es)
|
2013-07-25 |
2016-08-03 |
Novartis Ag |
Polipeptidos ciclicos para el tratamiento de insuficiencia cardiaca.
|
US9340582B2
(en)
|
2013-07-25 |
2016-05-17 |
Novartis Ag |
Bioconjugates of synthetic apelin polypeptides
|
CN105745222A
(zh)
|
2013-10-17 |
2016-07-06 |
西兰制药公司 |
酰化胰高血糖素类似物
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
CA2929107C
(en)
|
2013-11-06 |
2023-09-26 |
Zealand Pharma A/S |
Glucagon-glp-1-gip triple agonist compounds
|
TWI670281B
(zh)
|
2013-11-06 |
2019-09-01 |
西蘭製藥公司 |
Gip-glp-1雙重促效劑化合物及方法
|
ES2883345T3
(es)
|
2014-10-29 |
2021-12-07 |
Zealand Pharma As |
Compuestos agonistas del GIP y métodos
|
AU2016209968B2
(en)
|
2015-01-23 |
2018-11-29 |
Novartis Ag |
Synthetic apelin fatty acid conjugates with improved half-life
|
JP6989385B2
(ja)
|
2015-04-16 |
2022-01-05 |
ジーランド ファーマ アクティーゼルスカブ |
アシル化グルカゴン類似体
|
US20190290772A1
(en)
*
|
2016-06-02 |
2019-09-26 |
Indiana University Research And Technology Corporation |
Glucagon-like peptide-1-t3 conjugates
|
JOP20190086A1
(ar)
|
2016-10-21 |
2019-04-18 |
Novartis Ag |
مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
|
BR112019010624A2
(pt)
|
2016-12-09 |
2019-10-22 |
Zealand Pharma As |
agonistas duplos de glp-1/glp-2 acilados e composição
|
HRP20240485T1
(hr)
|
2017-08-24 |
2024-07-05 |
Novo Nordisk A/S |
Pripravci glp-1 i njihova upotreba
|
CN109836504B
(zh)
*
|
2017-11-24 |
2022-08-02 |
浙江道尔生物科技有限公司 |
一种治疗代谢疾病的多结构域活性蛋白
|
KR102647171B1
(ko)
|
2018-02-02 |
2024-03-15 |
노보 노르디스크 에이/에스 |
Glp-1 작용제 및 n-(8-(2-하이드록시벤조일)아미노)카프릴산의 염을 포함하는 고형 조성물
|
UY38072A
(es)
|
2018-02-07 |
2019-10-01 |
Novartis Ag |
Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
|
CN113166204A
(zh)
|
2018-11-27 |
2021-07-23 |
诺华股份有限公司 |
作为治疗代谢障碍的蛋白质原转换酶枯草杆菌蛋白酶/kexin 9型(PCSK9)抑制剂的环状肽
|
UY38485A
(es)
|
2018-11-27 |
2020-06-30 |
Novartis Ag |
Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
|
JP2022507958A
(ja)
|
2018-11-27 |
2022-01-18 |
ノバルティス アーゲー |
代謝障害の治療用のプロタンパク質転換酵素サブチリシン/ケキシン9型(pcsk9)阻害薬としての環状四量体化合物
|
GB201917723D0
(en)
|
2019-12-04 |
2020-01-15 |
Nv Rose Llc |
Stable liquid formulations of glucagon-like peptide 1 or analogues thereof
|
US20230082544A1
(en)
|
2020-02-18 |
2023-03-16 |
Novo Nordisk A/S |
Pharmaceutical formulations
|
CN115925995A
(zh)
|
2020-09-30 |
2023-04-07 |
北京质肽生物医药科技有限公司 |
多肽缀合物和使用方法
|
WO2023084449A1
(en)
|
2021-11-12 |
2023-05-19 |
Novartis Ag |
Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder
|
AR127698A1
(es)
|
2021-11-23 |
2024-02-21 |
Novartis Ag |
Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
|
CN114716533B
(zh)
*
|
2022-04-12 |
2023-04-14 |
北京惠之衡生物科技有限公司 |
一种酰化的长效glp-1衍生物
|
WO2024106505A1
(ja)
*
|
2022-11-16 |
2024-05-23 |
株式会社ポル・メド・テック |
豚臓器又はその由来物を含む移植材の製造方法
|